
               
               
               7 DRUG INTERACTIONS
               
               
                  
                     
                        
                           Agonistic effects with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, , tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids (7.1)
                           Antagonistic effects with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents (7.2)
                        
                     
                  
               
               
                  
                     
                     
                     7.1 Interactions that Augment Pressor Effect
                     
                        The increasing blood pressure effect of VAZCULEP is increased in patients receiving:
                        
                           Monoamine oxidase inhibitors (MAOI)
                           Oxytocin and oxytocic drugs
                           Tricyclic antidepressants 
                           Angiotensin, aldosterone
                           Atropine
                           Steroids, such as hydrocortisone
                           Norepinephrine transporter inhibitors, such as atomoxetine
                           Ergot alkaloids, such as methylergonovine maleate
                        
                     
                     
                  
               
               
                  
                     
                     
                     7.2 Interactions that Antagonize the Pressor Effect
                     
                        The increasing blood pressure effect of VAZCULEP is decreased in patients receiving: 
                        
                           α-adrenergic antagonists
                           Phosphodiesterase Type 5 inhibitors
                           Mixed α- and β-receptor antagonists
                           Calcium channel blockers, such as nifedipine
                           Benzodiazepines
                           ACE inhibitors
                           Centrally acting sympatholytic agents, such as reserpine, guanfacine.
                        
                     
                     
                  
               
            
         